Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pax

Showing results (211-220 of 220) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 220 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of lifeCiska Buijs, Sjoerd Rodenhuis, Caroline M Seynaeve, et al.
Neuromuscular Disorders : NMD|August 23, 2024
Performance of upper limb entry item to predict forced vital capacity in dysferlin-deficient limb girdle muscular dystrophyHolly Borland, Ursula Moore, Heather Gordish Dressman, et al.
Neurology. Genetics|November 3, 2025
Motor Function in Limb-Girdle Muscular Dystrophy R1/2A: Validation of Clinical Outcome Assessments for Clinical Care and Trial ReadinessMeredith K James, Megan A Iammarino, Natalie F Reash, et al.
Neurology. Genetics|April 6, 2026
Quantitative Measurement of Glycosylated ⍺-Dystroglycan as a Biomarker for Disease Severity in Limb-Girdle Muscular Dystrophy Type 2I/R9John Vissing, Tahseen Mozaffar, Nicholas E Johnson, et al.
International Journal of Cancer|July 22, 2009
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trialNinke Leffers, Annechien J A Lambeck, Marloes J M Gooden, et al.
Neuromuscular Disorders : NMD|February 21, 2021
Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same diseaseUrsula Moore, Heather Gordish, Jordi Diaz-Manera, et al.
American Journal of Hematology|March 18, 2022
COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US populationStephanie Berg, Seo-Hyun Kim, Amy Wozniak, et al.
Muscle & Nerve|February 18, 2022
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal studyUrsula Moore, Roberto Fernandez-Torron, Marni Jacobs, et al.
Frontiers in Neurology|April 1, 2022
Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis ApproachAnna G Mayhew, Meredith K James, Ursula Moore, et al.
Neurology|January 11, 2019
Assessment of disease progression in dysferlinopathy: A 1-year cohort studyUrsula Moore, Marni Jacobs, Meredith K James, et al.
Pageof 22

Showing results (211-220 of 220) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 220 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of lifeCiska Buijs, Sjoerd Rodenhuis, Caroline M Seynaeve, et al.
Neuromuscular Disorders : NMD|August 23, 2024
Performance of upper limb entry item to predict forced vital capacity in dysferlin-deficient limb girdle muscular dystrophyHolly Borland, Ursula Moore, Heather Gordish Dressman, et al.
Neurology. Genetics|November 3, 2025
Motor Function in Limb-Girdle Muscular Dystrophy R1/2A: Validation of Clinical Outcome Assessments for Clinical Care and Trial ReadinessMeredith K James, Megan A Iammarino, Natalie F Reash, et al.
Neurology. Genetics|April 6, 2026
Quantitative Measurement of Glycosylated ⍺-Dystroglycan as a Biomarker for Disease Severity in Limb-Girdle Muscular Dystrophy Type 2I/R9John Vissing, Tahseen Mozaffar, Nicholas E Johnson, et al.
International Journal of Cancer|July 22, 2009
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trialNinke Leffers, Annechien J A Lambeck, Marloes J M Gooden, et al.
Neuromuscular Disorders : NMD|February 21, 2021
Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same diseaseUrsula Moore, Heather Gordish, Jordi Diaz-Manera, et al.
American Journal of Hematology|March 18, 2022
COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US populationStephanie Berg, Seo-Hyun Kim, Amy Wozniak, et al.
Muscle & Nerve|February 18, 2022
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal studyUrsula Moore, Roberto Fernandez-Torron, Marni Jacobs, et al.
Frontiers in Neurology|April 1, 2022
Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis ApproachAnna G Mayhew, Meredith K James, Ursula Moore, et al.
Neurology|January 11, 2019
Assessment of disease progression in dysferlinopathy: A 1-year cohort studyUrsula Moore, Marni Jacobs, Meredith K James, et al.
Pageof 22